Torrent Pharmaceuticals Ltd - Stock Valuation and Financial Performance

BSE: 500420 | NSE: TORNTPHARM | Pharmaceuticals & Drugs | Large Cap

Torrent Pharma Share Price

2,513 -51.05 -1.99%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Torrent Pharma

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

Torrent Pharmaceuticals stock performance -

mw4me loader
P/E Ratio (CD):
58.09
Market Cap:
86,779.1 Cr.
52-wk low:
1,523.1
52-wk high:
2,745.6

Is Torrent Pharmaceuticals Ltd an attractive stock to invest in?

1. Is Torrent Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Torrent Pharmaceuticals Ltd is a good quality company.

2. Is Torrent Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of Torrent Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Torrent Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Torrent Pharmaceuticals Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Torrent Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Torrent Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 29.5%16.6%34%14.6%7.7%9.3%11.8%13.8%11%13.6%-
Value Creation
Index
1.20.22.00.3-0.3-0.20.10.20.00.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 4,1854,6536,6675,8165,9507,6737,9398,0058,5089,62010,319
Sales YoY Gr.-11.2%43.3%-12.8%2.3%29%3.5%0.8%6.3%13.1%-
Adj EPS 21.216.651.823.11419.5283628.336.344.1
YoY Gr.--21.8%212.1%-55.5%-39.1%38.8%43.5%28.8%-21.3%28.2%-
BVPS (₹) 56.273.6103.2128.5136.6139.6142.5172.5175.9183.1211.3
Adj Net
Profit
7185621,7537814756599461,2199591,2291,494
Cash Flow from Ops. 5998102,7421,0098941,7981,3932,0051,8032,368-
Debt/CF from Ops. 1.93.40.92.57.23.44.22.42.22.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9.7%10.1%6.6%13.1%
Adj EPS 6.2%20.9%9.1%28.2%
BVPS14%6%8.7%4.1%
Share Price 25.2% 21% 26.9% 62.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
43.225.658.619.910.614.119.822.916.320.222.4
Op. Profit
Mgn %
24.821.94123.722.525.827.33128.629.531.1
Net Profit
Mgn %
17.212.126.313.488.611.915.211.312.814.5
Debt to
Equity
0.61.10.70.61.41.31.20.80.70.9-
Working Cap
Days
20023818821612310510811711610794
Cash Conv.
Cycle
310-55-6-58-56-46-32-15-12

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 22.40%

Debt to equity has declined versus last 3 years average to 0.85

Sales growth is good in last 4 quarters at 13.34%

Sales growth has been subdued in last 3 years 6.61%

Net Profit has been subdued in last 3 years 9.11%

Latest Financials - Torrent Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 34.5 44.1
TTM Sales (₹ Cr.) 8,158 10,319
BVPS (₹.) 211.6 211.3
Reserves (₹ Cr.) 6,993 6,981
P/BV 12.12 12.14
PE 74.42 58.09
From the Market
52 Week Low / High (₹) 1523.10 / 2745.55
All Time Low / High (₹) 4.06 / 2745.55
Market Cap (₹ Cr.) 86,779
Equity (₹ Cr.) 169.2
Face Value (₹) 5
Industry PE 47.8

Management X-Ray of Torrent Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Torrent Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales4,1854,6536,6675,8165,9507,6737,9398,0058,5089,620
Operating Expenses 3,2333,6333,9374,4384,6095,6965,7695,5246,0776,796
Manufacturing Costs393443446610576691672674735726
Material Costs1,1081,2811,4321,6301,5352,0411,9821,9602,2312,513
Employee Cost 7418428429931,1351,4041,4291,4401,5261,678
Other Costs 9921,0671,2171,2051,3621,5601,6861,4511,5841,879
Operating Profit 9511,0202,7301,3771,3411,9762,1702,4802,4312,824
Operating Profit Margin (%) 22.7%21.9%40.9%23.7%22.5%25.8%27.3%31.0%28.6%29.4%
Other Income 38286229223307641215719763
Interest 59175184206308504451353255333
Depreciation 87191238307409618654658662707
Exceptional Items 00-19400-35700-4850
Profit Before Tax 8449402,3431,0889315621,1871,5261,2261,847
Tax 180189610155253125162274449602
Profit After Tax 6647511,7339346784361,0251,2527771,245
PAT Margin (%) 15.9%16.1%26.0%16.1%11.4%5.7%12.9%15.6%9.1%12.9%
Adjusted EPS (₹)19.622.251.227.620.012.930.337.023.036.8
Dividend Payout Ratio (%)25%25%34%25%35%66%53%47%105%60%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 1,9022,4913,4944,3504,6224,7244,8235,8375,9536,198
Share Capital 858585858585858585169
Reserves 1,8182,4063,4094,2664,5384,6404,7395,7535,8686,029
Minority Interest0000100000
Debt9552,5041,8532,2415,7374,8474,3953,6453,0464,261
Long Term Debt7442,1851,8502,2414,1113,9133,3042,9412,1232,496
Short Term Debt210319301,6269341,0917049231,765
Trade Payables1,4291,8282,2601,7492,0482,0972,0492,0671,6741,679
Others Liabilities 7179971,1671,0511,5592,0832,3102,1041,9332,330
Total Liabilities 5,0047,8208,7759,39213,96713,75113,57713,65312,60614,468

Fixed Assets

Gross Block1,4203,5433,7944,9109,4499,93510,33410,51210,72812,812
Accumulated Depreciation5457109341,2211,5952,1882,8013,4474,3064,690
Net Fixed Assets8752,8332,8593,6887,8557,7487,5337,0656,4238,121
CWIP 5346781,042519647617712889630765
Investments 1862987808044923532181226199
Inventories1,0061,0671,3581,5591,9661,9352,1482,6812,4622,230
Trade Receivables1,0991,5871,4459511,2531,4361,6491,5231,6321,944
Cash Equivalents 769567647894867816667604403571
Others Assets534789644977886846865710829638
Total Assets 5,0047,8208,7759,39213,96713,75113,57713,65312,60614,468

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 5998102,7421,0098941,7981,3932,0051,8032,368
PBT 8449402,3431,0889315621,1871,5261,2261,847
Adjustment 1373385524306071,4188769931,350937
Changes in Working Capital -120-409424-125-36099-386-338-352-18
Tax Paid -262-58-577-384-284-281-284-176-421-398
Cash Flow From Investing Activity -356-2,162-838-787-4,707-241199-449-197-2,415
Capex -398-236-592-486-789-661-403-334-196-415
Net Investments 1116-20-17538395585-121-8-13
Others 32-1,942-226-126-3,956241757-1,987
Cash Flow From Financing Activity 861,212-1,435-1933,417-1,314-1,549-1,651-1,78177
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 3421,516-652052,339238-451-543-1,033423
Interest Paid -61-195-212-191-276-503-485-356-258-303
Dividend Paid -267-200-840-204-265-310-719-338-677-863
Others 7391-319-31,619-740106-413187820
Net Cash Flow 330-14046929-39524242-95-17530
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)39.9434.1957.9223.815.129.3421.4723.4913.1820.5
ROCE (%)35.0626.9845.6320.3613.819.7515.2817.6214.3520.32
Asset Turnover Ratio0.960.730.810.640.961.051.091.091.161.21
PAT to CFO Conversion(x)0.91.081.581.081.324.121.361.62.321.9
Working Capital Days
Receivable Days781058375363438393840
Inventory Days84816691574950596252
Payable Days411464521449451371382383306244

Torrent Pharmaceuticals Ltd Stock News

Torrent Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Torrent Pharma on 28-Mar-2024 16:01 is ₹2,513.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Torrent Pharma stood at ₹86,779.1.
The latest P/E ratio of Torrent Pharma as of 28-Mar-2024 16:01 is 74.42.
The latest P/B ratio of Torrent Pharma as of 28-Mar-2024 16:01 is 12.12.
The 52-week high of Torrent Pharma is ₹2,745.6 and the 52-week low is ₹1,523.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Torrent Pharma is ₹8,158 ( Cr.) .

About Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in many countries.

The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with 90 year old Heumann from Pfizer to enter the German market. Later on purchased ANDA of Minocycline from Ranbaxy for the US Market in 2015. In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility. Torrent Pharma is committed towards ‘not just healthcare but lifecare’.

Business area of the company

Torrent Pharmaceuticals has established itself as a major player in the Indian Pharma arena. The company has well segregated marketing divisions, strategically structured on specific therapeutic areas and enjoys dominance in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). With Unichem's domestic business acquisition, Torrent has entered the list of top pharma firms in the Indian Pharma Market (IPM) and is ranked No 8 in the IPM.

Manufacturing facilities

The company’s manufacturing facilities are loaced at Indrad, Dahej, Baddi, Sikkim Unit I & II, Sikkim Unit III, Vizag, Pithampur, Levittown Pennsylvania and HSE Forum.

Awards and recognition

  • 1984-85 Received Chemexcil Export Award
  • 1984-85 Received Udyog Ratna Award
  • 1985-86 Received Chemexcil Export Award
  • 1986-87 Received Chemexcil Export Award
  • 1986-87 Received IDMA Quality Excellence Award
  • 1986-87 Received Export Award from Govt. of Gujarat
  • 1987-88 Received Export Award from Govt. of Gujarat
  • 1989-90 Received Chemexcil Trishul Award for highest Pharma Exports
  • 1989-90 Received IDMA Quality Excellence Award
  • 1988-89 Received Chemexcil Export Award
  • 1990-91 Received Export Award from Govt. of Gujarat
  • 1990-91 Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship
  • 1991-92 Received Export Award from Govt. of Gujarat
  • 1991-92 Received National Export Award
  • 1992-93 Received IDMA Quality Excellence Award
  • 1999-00 GCCI Export Appreciation Award
  • 1999-00 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility.
  • 2000-01 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
  • 2001-02 Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
  • 2001-02 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy forits API manufacturing facility
  • 2002-03 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
  • 2009-10 Baddi Plant awarded Five Star rating by British Safety Council
  • 2012-13 Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
  • 2014-15 Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
  • 2017-18 Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
  • 2017-18 Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category

Accreditation

Approvals research centre

  • National GLP Compliance Monitoring Authority, India*
  • National Accreditation Board for Testing & Calibration Laboratories (NABL), India*
  • ISO 14001:2004 and OHSAS 18001:2007, ISOQAR Ltd., UK*
  • ISO 50001 : 2011, ISOQAR Ltd. UK*

(*Also applicable for Bio-Evaluation Center)

Bio-evaluation centre accreditations

  • The Drug Controller General (India) (DCGI)
  • ANVISA (BRAZIL)
  • Ministry of Health (UAE)

Studies inspected and approved

  • USFDA
  • AFFSAPS (ANSM)
  • DKMA
  • AGES
  • ANVISA

Studies accepted by Regulatory Agencies in:

  • Russia
  • CIS Countries
  • Australia
  • ASEAN countries
  • South Africa
  • African countries
  • South American countries

Milestones

  • 1959: U. N. Mehta started Pharma operations.
  • 1971: Trinity Laboratories renamed as Torrent Pharmaceuticals Limited.
  • 1980: First manufacturing facility set up at Vatva in Ahmedabad
  • 1983: Entry into the international markets. First Export order to USSR received
  • 1984: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1984: Torrent Laboratories Limited received Udyog Ratna Award.
  • 1985: Torrent Laboratories Limited received IMC Golden Jubilee Endowment Award for Export Performance.
  • 1985: Torrent Exports Limited received Export Award From Govt. of Gujarat.
  • 1985: Torrent Laboratories Limited received IDMA Quality Excellence Award.
  • 1985: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1986: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1986: Torrent Laboratories Limited received IDMA Quality Excellence Award.
  • 1986: Torrent Exports Limited received Export Award from Govt. of Gujarat.
  • 1987: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1987: Torrent Exports Limited received Export Award from Govt. of Gujarat.
  • 1989: Second manufacturing plant commissioned at Indrad
  • 1989: Torrent Exports Limited received Chemexcil Trishul Award for highest Pharma Exports.
  • 1989: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
  • 1988: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1990: Torrent Exports Limited received National Export Award.
  • 1990: Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship.
  • 1992: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
  • 1995: Torrent Gujarat Biotech Limited plant commissioned.
  • 1996: U N Mehta bestowed with the title of Corporate Business Man of the Year
  • 1998: Torrent Exports renamed as Torrent Ltd. as part of restructuring and consolidation exercise.
  • 1998: State-of-the-art R&D Centre commissioned.
  • 1998: Torrent Pharmaceuticals Limited acquires Pharma related investments and business of Torrent Exports Limited.
  • 1999: Restructuring of Torrent Pharmaceuticals Ltd. through formation of three new divisions – Prima, Vista, Psycan.
  • 1999: First New Chemical Entity Patented by Torrent Research Center
  • 1999: GCCI Export Appreciation Award
  • 1999: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
  • 2000: Torrent Research Centre received OECD Standards of Good Lab. Practices Certificate from Dutch Health Ministry.
  • 2000: Indrad Plant received ISO 9001:2000 Certificate
  • 2001: Torrent Pharma ranked in the top 10 Indian Companies in terms of Return on Capital Employed (ET - BCG Study Feb - 2001).
  • 2001: Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation
  • 2001: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy for its API manufacturing facility
  • 2001: Torrent do Brasil Ltda. set up in Brazil
  • 2002: Discovered and patented AGE (Advanced Glycosylation End-products) molecule.
  • 2002: Torrent Pharma's Indrad Plant receives ISO 14001:1996 and OHSAS 18001:1999
  • 2002: Torrent's R&D Centre received ISO/IEC 17025:1999 for its facilities by National Accreditation 2002:
  • 2002: Board for Testing and Calibration Laboratories (NABL).
  • 2002: Addition of a new marketing division, MIND
  • 2002: Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate / Matrix Based SR / Modified Release Formulations developed indigenously by Torrent Research Center (2002)
  • 2002: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
  • 2002: Brazilian Sanitary Surveillance Agency accredited Torrent's R&D Centre with ANVISA, authorizing it to conduct Bioequivalance Studies.
  • 2003: Torrent Pharma Inc. set up in USA.
  • 2003: GMP Certification received from European Union by Torrent Pharmaceuticals Manufacturing Plant
  • 2003: Torrent Pharma Philippines Inc. set up.
  • 2004: Torrent Pharma's manufacturing facility at Indrad received MHRA (UK) and TGA (Australia) approvals
  • 2004: Restructuring of marketing divisions and addition of new division, Delta.
  • 2004: Torrent Australasia Pty Ltd. incorporated in Australia
  • 2005: New manufacturing unit at Baddi, Himachal Pradesh, set up to cater to domestic formulations market.
  • 2005: Torrent Pharma signed an agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk.
  • 2005: Acquired Heumann Pharma GmbH & Co Generica KG, a Pfizer group company, in Germany.
  • 2005: Two new marketing divisions- AXON and NEURON set up to cater to neuropsychiatry segment.
  • 2005: Entered into a research collaboration with AstraZeneca for developing novel anti-hypertensive drug.
  • 2005: Torrent Pharma's QC department at Chhatral manufacturing plant accredited with ISO/IEC- 17025 by NABL
  • 2006: The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got US FDA approval
  • 2006: Torrent Pharma and Pharma Dynamics (Pty) Ltd, South Africa signed a Technical Agreement for supplies of a range of products
  • 2007: Indrad Plant certified with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System) and OHSAS 180001:1999 (Occupational Health and Safety Management System) by ISOQAR, UKAS accredited body
  • 2007: Construction of Sikkim Plant started
  • 2008: Baddi Plant received GMP certification from Government of Upper Bavaria, Germany
  • 2009: Commissioned dedicated formulation and packaging unit for manufacturing Insulin exclusively for Novo Nordisk
  • 2009: Entered into license and supply agreement with AstraZeneca for marketing its products in international market
  • 2009: Baddi Plant awarded Five Star rating by British Safety Council
  • 2010: Baddi Plant received OHAS Audit 18001:2007certification; facility approved by the regulatory authority of Uganda
  • 2010: An advanced facility for Stability Studies set up at Indrad Plant
  • 2010: Entered into the therapeutic area of Gynaecology
  • 2010: Commenced commercial operations of Laboratories Torrent S.A. de C.V., Mexico
  • 2010: Started construction of Dahej manufacturing facility
  • 2010: Commissioned a subsidiary in United Kingdom and Romania
  • 2010: Torrent Research Center develops Long Acting Injectables technology
  • 2010: Foray into oncology segment
  • 2011: Sikkim Plant commences operation
  • 2011: Indigenous Nasal Drug Delivery system developed by Torrent Research Center
  • 2011: Set up Sparsh, a dedicated division to cater to Dermatology Segment
  • 2012: Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
  • 2012: Topical Foams system developed by Torrent Research Center
  • 2013: Torrent Pharma enters into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab
  • 2014: Acquired Elder Pharma's identified Indian Branded Formulation Business in India and Nepal
  • 2014: Launched Nephro, a dedicated division to cater to the Nephrology Segment
  • 2014: Torrent Pharma's Dahej Plant commences operations
  • 2015: Torrent acquires 100% stake of Zyg Pharma
  • 2015: Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
  • 2016: Dahej Plant receives USFDA approval
  • 2016: Acquired API manufacturing Unit of Hyderabad based Glochem Industries Limited
  • 2017: Acquired Unichem’s Domestic and Nepal business and also its Sikkim manufacturing facility.
  • 2017: Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
  • 2017: Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category
  • 2017: Acquired Women Healthcare brands from Novartis
  • 2018: Acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.
  • 2019: Torrent & Glenmark sign licensing agreement for co-marketing of Remogliflozin Etabonate in India
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.